CDV3 (carnitine deficiency-associated gene expressed in ventricle-3) is a cytoplasmic protein with emerging roles in metabolic and disease processes. Originally identified as an upregulated gene in cardiomyopathic ventricles of carnitine-deficient mice, CDV3 exists as alternatively spliced isoforms (236 and 281 amino acids) sharing conserved N-terminal regions 1. The protein shows homology to nuclear proteins dysregulated in c-erbB-2-overexpressing breast cancer cells 1. CDV3 has been identified as a differentially expressed protein across multiple pathological contexts. Proteomic studies reveal CDV3 upregulation in colorectal adenomas and adenocarcinomas compared to normal mucosa, suggesting potential involvement in tumorigenesis 2. The protein was also detected among candidates dysregulated in homocysteine-induced vascular smooth muscle cell transformation into foam cells, implicating it in atherosclerosis pathogenesis 3. Additionally, CDV3 expression changes in response to low oxygen tension in chondrosarcoma cells 4, and genetic variants in CDV3 may modulate colorectal cancer risk 5. Recent metabolic studies identified CDV3 among genes strongly correlated with obesity-related metabolic derangements and predictive of weight regain, suggesting roles in metabolic homeostasis 6. Furthermore, CDV3 was detected as a protein regulated by antidepressant treatment in prefrontal cortex, supporting synaptic and mitochondrial homeostasis in depression models 7. These findings suggest CDV3 functions across cancer biology, metabolic regulation, cardiovascular pathology, and neuropsychiatric disease.